The major objective of this application is to seek an understanding of the-intracellular signalling mechanisms by which dopamine exerts its effects in striatal neurons in the basal ganglia. This includes an understanding not only of the intracellular messengers that mediate the dopaminergic signal but also an understanding of how this signal is integrated together with that of a variety of other neurotransmitters impinging on striatal neurons. A major goal of the proposed studies is to generate, by novel technologies, genetically altered animals that will serve as models in which to study dopamine signalling pathways. These studies will allow the characterization of the involvement of individual components of the dopaminergic signalling pathways without the use of non-specific inhibitors. In addition, it also allows the analysis of the effect of these mutations in whole animals in which the complexity of interacting neurotransmitter pathways is preserved in the basal ganglia as well as other brain regions. Additional goals of the proposed studies are to use recently introduced molecular biological techniques to identify novel components of the dopamine signalling pathways. Specifically the yeast two-hybrid technique will be used to isolate proteins that interact with the phosphoproteins or with the enzymes that regulate their phosphorylation and dephosphorylation. These studies will be of particular importance in understanding such diseases as Parkinson's disease and schizophrenia which result in part from defects in dopamine- signalling pathways. In addition, the availability of mouse models in which specific components of dopamine-signalling pathways are deficient may be useful in the development of new therapeutic strategies for the treatment of such diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Program Projects (P01)
Project #
5P01MH040899-12
Application #
5214600
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
12
Fiscal Year
1996
Total Cost
Indirect Cost
Plattner, Florian; Hayashi, Kanehiro; Hernández, Adan et al. (2015) The role of ventral striatal cAMP signaling in stress-induced behaviors. Nat Neurosci 18:1094-100
Kimura, Toru; Han, Wonsun; Pagel, Philipp et al. (2011) Protein phosphatase 2A interacts with the Na,K-ATPase and modulates its trafficking by inhibition of its association with arrestin. PLoS One 6:e29269
Zhou, Mingming; Rebholz, Heike; Brocia, Christine et al. (2010) Forebrain overexpression of CK1delta leads to down-regulation of dopamine receptors and altered locomotor activity reminiscent of ADHD. Proc Natl Acad Sci U S A 107:4401-6
Bertran-Gonzalez, Jesus; HÃ¥kansson, Kerstin; Borgkvist, Anders et al. (2009) Histone H3 phosphorylation is under the opposite tonic control of dopamine D2 and adenosine A2A receptors in striatopallidal neurons. Neuropsychopharmacology 34:1710-20
Kuroiwa, Mahomi; Bateup, Helen S; Shuto, Takahide et al. (2008) Regulation of DARPP-32 phosphorylation by three distinct dopamine D1-like receptor signaling pathways in the neostriatum. J Neurochem 107:1014-26
Nishi, Akinori; Kuroiwa, Mahomi; Miller, Diane B et al. (2008) Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J Neurosci 28:10460-71
Kimura, Tohru; Allen, Patrick B; Nairn, Angus C et al. (2007) Arrestins and spinophilin competitively regulate Na+,K+-ATPase trafficking through association with a large cytoplasmic loop of the Na+,K+-ATPase. Mol Biol Cell 18:4508-18
Svenningsson, Per; Greengard, Paul (2007) p11 (S100A10)--an inducible adaptor protein that modulates neuronal functions. Curr Opin Pharmacol 7:27-32
Barbano, Paolo E; Spivak, Marina; Flajolet, Marc et al. (2007) A mathematical tool for exploring the dynamics of biological networks. Proc Natl Acad Sci U S A 104:19169-74
Borgkvist, Anders; Usiello, Alessandro; Greengard, Paul et al. (2007) Activation of the cAMP/PKA/DARPP-32 signaling pathway is required for morphine psychomotor stimulation but not for morphine reward. Neuropsychopharmacology 32:1995-2003

Showing the most recent 10 out of 219 publications